ST吉药(300108) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥151,879,835.67, a decrease of 22.79% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥71,999,121.20, down 35.60% year-on-year, while the year-to-date net profit reached -¥306,362,090.68, an increase of 54.24%[3]. - The company reported a net loss of ¥310,099,673.46 for the quarter, compared to a net loss of ¥206,130,118.79 in the same period last year, indicating a worsening of 50.5%[31]. - The gross profit margin decreased, with operating profit recorded at -¥279,789,227.91, compared to -¥200,894,770.26 in the previous year[29]. - Basic and diluted earnings per share were both reported at -0.4600, compared to -0.2982 in the previous year, indicating a decline in shareholder value[31]. Cash Flow and Liquidity - The cash flow from operating activities showed a net outflow of ¥66,334,718.94, representing a 139.97% decline compared to the beginning of the year[3]. - The company's cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[33]. - The net cash flow from operating activities was ¥66,334,718.94, a significant improvement from the previous period's net cash flow of -¥165,976,746.60[34]. - Cash inflows from operating activities totaled ¥441,383,406.42, down 29.9% from ¥629,689,609.80 in the prior period[34]. - Cash outflows from operating activities decreased to ¥375,048,687.48, a reduction of 52.9% compared to ¥795,666,356.40 in the previous period[34]. - The ending balance of cash and cash equivalents was ¥8,103,627.77, down from ¥30,074,419.06 in the previous period[36]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,521,313,888.19, a decrease of 7.97% from the end of the previous year[3]. - The total assets decreased from ¥2,739,752,697.28 to ¥2,521,313,888.19, a decline of 8.0%[25]. - Total liabilities increased to ¥2,808,373,398.36 from ¥2,712,552,815.99, marking a rise of 3.5%[25]. - The company's total equity attributable to shareholders decreased to -¥274,890,356.12 from ¥31,471,734.56, reflecting a negative shift in financial health[25]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,773[13]. - The largest shareholder, Sun Jun, holds 19.13% of shares, totaling 127,388,759 shares, with 95,541,569 shares pledged[13]. - The second-largest shareholder, Lu Zhongkui, holds 17.94% of shares, totaling 119,459,946 shares, with 115,334,235 shares pledged[13]. - The company has a significant number of shares pledged by major shareholders, indicating potential liquidity risks[13]. Income and Expenses - Financial expenses for the period amounted to ¥125,153,670.15, an increase of 43.62% year-on-year, attributed to overdue bank loans and rising interest rates[9]. - Other income decreased by 85.56% to ¥1,351,332.67, primarily due to a reduction in government subsidies received[9]. - The company reported an increase of 606.94% in non-operating income to ¥6,325,579.98, mainly due to tax reductions granted by the government[9]. - Research and development expenses were reported at ¥11,334,977.57, slightly up from ¥10,269,927.57, indicating continued investment in innovation[29]. Inventory and Receivables - The accounts receivable balance decreased by 29.11% to ¥252,894,778.39, mainly due to the provision for bad debts[8]. - Accounts receivable decreased to ¥252,894,778.39 from ¥356,718,305.95 at the end of 2020[21]. - Inventory increased to ¥297,571,442.08 from ¥291,929,087.26 at the end of 2020[21]. Future Outlook - The company is focusing on expanding its market presence and developing new products, although specific details were not provided in the report[18]. - Future guidance and performance outlook were not explicitly detailed in the available documents[18].